Clinicopathologic characterization of malignant chondroblastoma: a neoplasm with locally aggressive behavior and metastatic potential that closely mimics chondroblastoma-like osteosarcoma

Konishi, 2017, Chondroblastoma of extra-craniofacial bones: clinicopathological analyses of 103 cases, Pathol Int, 67, 495, 10.1111/pin.12586 Lu, 2019, Histone H3K36M mutation and trimethylation patterns in chondroblastoma, Histopathology, 74, 291, 10.1111/his.13725 Kilpatrick SE, Romeo S. Chondroblastoma. In: Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F, editors. WHO classification of tumours of soft tissue and bone, 4th ed. Lyon, France: IARC Press; 2013. p. 240, 262–3. Amary F, Bloem JL, Cleven AHG, Konishi E. Chondroblastoma. In: WHO Classification of Tumours Editorial Board. WHO classification of soft tissue and bone tumours, 5th ed. Lyon, France: IARC Press; 2020. Amary, 2017, H3F3A (Histone 3.3) G34W immunohistochemistry, Am J Surg Pathol, 41, 1059, 10.1097/PAS.0000000000000859 Schaefer, 2018, Immunohistochemistry for histone H3G34W and H3K36M is highly specific for giant cell tumor of bone and chondroblastoma, respectively, in FNA and core needle biopsy, Cancer Cytopathol, 126, 552, 10.1002/cncy.22000 Amary, 2016, The H3F3 K36M mutant antibody is a sensitive and specific marker for the diagnosis of chondroblastoma, Histopathology, 69, 121, 10.1111/his.12945 Mayo-Smith, 1990, Chondroblastoma of the rib. A case report and review of the literature, Clin Orthop Relat Res, 251, 230, 10.1097/00003086-199002000-00038 Al Hmada, 2020, Chondroblastoma-like Osteosarcoma, Arch Pathol Lab Med, 144, 15, 10.5858/arpa.2019-0191-RA Kyriakos, 1985, Metastatic chondroblastoma. Report of a fatal case with a review of the literature on atypical, aggressive, and malignant chondroblastoma, Cancer, 55, 1770, 10.1002/1097-0142(19850415)55:8<1770::AID-CNCR2820550825>3.0.CO;2-Q Huvos AG, Higinbotham NL, Marcove RC, O'Leary P. Aggressive chondroblastoma. Review of the literature on aggressive behavior and metastases with a report of one new case. Clin Orthop Relat Res. 1977;126:266–72. Hull, 1977, Aggressive chondroblastoma. Report of a case with multiple bone and soft tissue involvement, Clin Orthop Relat Res, 126, 261 Lin, 2005, Treatment and prognosis of chondroblastoma, Clin Orthop Relat Res, 438, 103, 10.1097/01.blo.0000179591.72844.c3 Oda, 2007, Pigmented villonodular synovitis with chondroid metaplasia, resembling chondroblastoma of the bone: a report of three cases, Mod Pathol, 20, 545, 10.1038/modpathol.3800770 Dahlin, 1972, Benign chondroblastoma. A study of 125 cases, Cancer, 30, 401, 10.1002/1097-0142(197208)30:2<401::AID-CNCR2820300216>3.0.CO;2-B John, 2020, Chondroblastomas presenting in adulthood: a study of 39 patients with emphasis on histological features and skeletal distribution, Histopathology, 76, 308, 10.1111/his.13972 Behjati, 2013, Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone, Nat Genet, 45, 1479, 10.1038/ng.2814 Tate, 2019, COSMIC: the catalogue of somatic mutations in cancer, Nucleic Acids Res, 47, D941, 10.1093/nar/gky1015 Lu, 2016, Histone H3K36 mutations promote sarcomagenesis through altered histone methylation landscape, Science, 352, 844, 10.1126/science.aac7272 Fang, 2016, The histone H3.3K36M mutation reprograms the epigenome of chondroblastomas, Science, 352, 1344, 10.1126/science.aae0065 Saba, 2019, Genetic profiling of a chondroblastoma-like osteosarcoma/malignant phosphaturic mesenchymal tumor of bone reveals a homozygous deletion of CDKN2A, intragenic deletion of DMD, and a targetable FN1-FGFR1 gene fusion, Genes Chromosom Cancer, 58, 731, 10.1002/gcc.22764 Chen, 2014, Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma, Cell Rep., 7, 104, 10.1016/j.celrep.2014.03.003 Perry, 2014, Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma, Proc Natl Acad Sci USA, 111, E5564, 10.1073/pnas.1419260111 Kovac, 2015, Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency, Nat Commun, 6, 1, 10.1038/ncomms9940 Engert, 2017, Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics, Oncotarget, 8, 48794, 10.18632/oncotarget.10720